|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
This 4-part mini-series is designed to equip pharmacists with knowledge and skills needed to conduct antimicrobial stewardship research. It provides a self-study review of idea generation, protocol development, data collection set-up and management, data analysis, and research dissemination. This content is meant to supply the participant with fundamental knowledge needed to measure outcomes related to antimicrobial stewardship programs.
The target audience for this activity includes pharmacists and board-certified infectious diseases pharmacists (BCIDPs). At the completion of this activity, the participant will be able to:
Getting Started with Research
Navigating Study Design and Data Capture in Antimicrobial Stewardship Research
Interpreting and Analyzing Data
Disseminating Research Findings
Michael D. Nailor, PharmD, BCPS
Clinical Specialist-Infectious Diseases, St. Joseph’s Hospital and Medical Center
Michael P. Veve, PharmD, MPH
Clinical Assistant Professor, College of Pharmacy, University of Tennessee Health Science Center
Jessina C. McGregor, PhD FSHEA
Associate Professor, Oregon State University College of Pharmacy
Meghan Jeffres, PharmD, BCIDP
Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy
Release Date: 11-01-2020
ACPE Expiration Date: 11-01-2023
BCIDP Expiration Date: 11-01-2023
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-20-511-H04-P, 0221-9999-20-512-H04-P, 0221-9999-20-513-H04-P and 0221-9999-20-514-H04-P have been assigned to these home study, knowledge-based activities. This activity is approved for 4.0 contact hours (0.4 CEU) total in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required on each module to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation for each module. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 11/01/2020 and was extended as of 11/1/2021 for this activity and is available for one year from this date.
Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the joint program offered by the Society of Infectious Diseases Pharmacists (SIDP), the American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Michael Nailor is an Advisory Board member for AbbVie, Merck, and Shionogi. Michael Veve has served as a Research Prinicipal Investigator for grants received from Cumberland Pharmaceuticals and Paratek Pharmaceuticals, and is an Advisory Board member for Merck and Summit Therapeutics. Jessina McGregor does not have any relevant commercial and/or financial relationships to disclose. Meghan Jeffres does not have any relevant commercial and/or financial relationships to disclose.
This activity is provided by ProCE, Inc. and SIDP.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.